Advanced Asset Management Advisors Inc bought a new stake in Bristol-Myers Squibb Co (NYSE:BMY) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 30,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,838,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BMY. Advisor Partners LLC grew its position in shares of Bristol-Myers Squibb by 6.9% during the third quarter. Advisor Partners LLC now owns 36,961 shares of the biopharmaceutical company’s stock worth $2,356,000 after buying an additional 2,382 shares in the last quarter. Israel Discount Bank of New York lifted its stake in Bristol-Myers Squibb by 31.8% during the second quarter. Israel Discount Bank of New York now owns 10,515 shares of the biopharmaceutical company’s stock worth $586,000 after purchasing an additional 2,540 shares during the last quarter. Van ECK Associates Corp lifted its stake in Bristol-Myers Squibb by 0.7% during the third quarter. Van ECK Associates Corp now owns 791,275 shares of the biopharmaceutical company’s stock worth $50,436,000 after purchasing an additional 5,451 shares during the last quarter. Aperio Group LLC lifted its stake in Bristol-Myers Squibb by 12.7% during the third quarter. Aperio Group LLC now owns 854,457 shares of the biopharmaceutical company’s stock worth $54,463,000 after purchasing an additional 96,561 shares during the last quarter. Finally, D.A. Davidson & CO. lifted its stake in Bristol-Myers Squibb by 8.6% during the third quarter. D.A. Davidson & CO. now owns 205,789 shares of the biopharmaceutical company’s stock worth $13,117,000 after purchasing an additional 16,310 shares during the last quarter. 71.49% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

Several equities research analysts recently weighed in on the company. Argus restated a “buy” rating and set a $66.43 target price (down previously from $75.00) on shares of Bristol-Myers Squibb in a research note on Wednesday. Leerink Swann boosted their target price on Bristol-Myers Squibb from $71.00 to $76.00 and gave the stock a “positive” rating in a research note on Tuesday, February 6th. Vetr upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 target price for the company in a research note on Thursday, February 1st. BMO Capital Markets decreased their target price on Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating for the company in a research note on Tuesday, February 6th. Finally, Citigroup set a $78.00 target price on Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Friday, February 16th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $66.79.

Shares of Bristol-Myers Squibb stock opened at $66.10 on Thursday. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb Co has a 52 week low of $51.56 and a 52 week high of $70.05. The firm has a market capitalization of $107,864.76, a P/E ratio of 112.03, a price-to-earnings-growth ratio of 2.03 and a beta of 0.98.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The company had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same quarter in the previous year, the business earned $0.63 earnings per share. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. equities research analysts expect that Bristol-Myers Squibb Co will post 3.2 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.42%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s payout ratio is currently 271.19%.

ILLEGAL ACTIVITY WARNING: “Advanced Asset Management Advisors Inc Buys New Stake in Bristol-Myers Squibb Co (BMY)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/advanced-asset-management-advisors-inc-buys-new-stake-in-bristol-myers-squibb-co-bmy/1955027.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.